Stockreport
Cellectis Announces Two Oral Presentations and One Poster Presentation at the 2017 ASH Annual Meeting

Last cellectis sa american deposi earnings: 5/9 04:31 pm
Check Earnings Report
US:NASDAQ Investor Relations: cellectis.com/en/investors
PDF
NEW YORK--(BUSINESS WIRE)-- Regulatory News: Cellectis (Paris:ALCLS) (NASDAQ:CLLS) (Alternext: ALCLS - Nasdaq: CLLS), a clinical-stage biopharmaceutical company focused on developing immunotherapies based on gene-edited allogeneic CAR T-cells (UCART), announced today that abstracts regarding the Company's allogeneic, off-the-shelf, CAR T product candidates have been accepted for presentation at the 59th American Society of Hematology (ASH) Annual Meeting and Exposition. The meeting will be held from December 9 to 12, 2017 in Atlanta, GA. Oral presentations: UCARTCS1 product candidate targeting Multiple Myeloma 502. Universal SLAMF7-Specific CAR T-Cells As Treatment for Multiple Myeloma Abstract: https://ash.confex.com/ash/2017/webprogram/Paper106073.htmlSession Name: 652. Myeloma: Pathophysiology and Pre-Clinical Studies, excluding Therapy: Nov
[Read more]
IMPACT SNAPSHOT | EVENT TIME: | CLLS | ||||
---|---|---|---|---|---|---|
Last Price
|
Price Change
|
Price Change %
|
Volume Shares
|
Max Up
|
Max Down
|
Volume Ratio
%
|
Performance comparison
Updated
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
LAST PRICE | ||
VWAP | ||
High:
|
MAX UP |
High:
|
Low:
|
MAX DOWN |
Low:
|
%
|
POST NEWS RANGE |
%
|
|
PRICE CHANGE |
|
|
PRICE CHANGE PERCENTAGE |
|
|
S&P 500 (SPX) |
|
%
|
VOLUME RATIO |
%
|
VOLUME (SHARES) | ||
TICKS | ||
|
AVG SHARES PER TRADE |
|
Don't Miss Out On The Next BIG Stock Move
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS
Be the first to know
Opt in for alerts from News Quantifed
Opt-in for
CLLS alerts
CLLS alerts
from News Quantified
Movers & Shakers
The biggest gainers and losers and WHY it moved
CLLS alerts
High impacting CELLECTIS SA AMERICAN DEPOSI news events
Weekly update
A roundup of the hottest topics
CLLS
NEWS
NEWS
- Rawadi named CEO of LNC Therapeutics [Reuters][Reuters]
- Cellectis to Present Data at the 2018 AACR Annual Meeting[Business Wire]
- Cellectis Announces Closing of Follow-On Offering[Business Wire]
- Is Cellectis SA Stock a Buy Now? [The Motley Fool][The Motley Fool]
- Cellectis: Monthly Information on Share Capital and Company Voting Rights[Business Wire]
- More
CLLS
SEC Filings
SEC Filings
- 4/13/18 - Form S-8
- 4/11/18 - Form 6-K
- 4/10/18 - Form 6-K
- CLLS's page on the SEC website
- More